Infertility News and Research

RSS

Infertility primarily refers to the biological inability of a person to contribute to conception. Infertility may also refer to the state of a woman who is unable to carry a pregnancy to full term.

Alcohol during pregnancy affects fertility of unborn son: Study

According to new research a mother drinking alcohol during pregnancy can significantly affect the fertility of her unborn male offspring. The Danish study involved 347 young men aged 18 to 21 and found that those whose mothers had drunk more than four drinks a week during pregnancy had one third the sperm levels compared to those whose mothers were teetotalers.

29 Jun 2010

Genetic variation can impact women's response to ovarian stimulating hormones

Researchers have discovered that some women carry a genetic variation that makes them sub-fertile and less likely to respond to ovarian stimulating hormones during fertility treatment. The discovery opens the way to identifying these women and devising personalised fertility treatments that could bypass the problem caused by the genetic abnormality.

29 Jun 2010

Overweight women undertaking ART at increased risk of miscarriage

Being overweight leads to a greater risk of miscarriage for patients undergoing assisted reproductive technology (ART), the 26th annual conference of the European Society of Human Reproduction and Embryology heard today (Monday). Dr. Vivian Rittenberg, a Clinical Fellow in the Assisted Conception Unit, Guy's and St. Thomas' Hospital NHS Foundation Trust, London, UK, said that her research provided additional evidence to show that increased body mass index (BMI) was independently associated with a higher miscarriage rate after IVF or ICSI treatment.

28 Jun 2010

German IVF Register reports one-millionth treatment cycle in reproductive medicine

Dr. Klaus Buhler, President of the German IVF Register, has reported the one-millionth treatment cycle in reproductive medicine recorded by the IVF Register in Germany this year. Presently, ninety per cent of all centers for in-vitro fertilization (IVF) in Germany collect data from reproductive treatments using RecDate Advance by Merck Serono - a database system developed by the IT consulting firm CRITEX, and marketed under the name MedITEX IVF.

23 Jun 2010

Women with PCOS may be more vulnerable to BPA exposure: Study

Women with the polycystic ovary syndrome, the most common hormone imbalance in women of reproductive age, may be more vulnerable to exposure to the chemical bisphenol A, found in many plastic household items, according to a new study. The results will be presented Sunday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Exposure to BPA in early life may affect testis function into adulthood

Exposure to environmental levels of the industrial chemical bisphenol A, or BPA, in the womb and early life may cause long-lasting harm to testicular function, according to a new study conducted in animals. The results are being presented Monday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010

Vitrolife acquires 25% participation in HertART Aps

Vitrolife has entered an agreement with the Danish company HertART Aps with regard to product development and distribution of IVF products and at the same time acquires a participation of 25 percent in the company.

18 Jun 2010

“Experiment” with homeopathy killed a cancer patient: Inquest

Doctor Peter Dingle at an inquest into the events that led to the death of his wife Penelope, 45 on 25th August 2005 revealed that he had argued with her decision to go for alternative therapies as her colorectal cancer treatment.

17 Jun 2010

Merck Serono, EMD Serono resume Stimuvax clinical program for NSCLC

Merck Serono, a division of Merck KGaA, and its U.S. affiliate, EMD Serono, Inc. today announced that they are resuming their Stimuvax® (BLP25 liposome vaccine) clinical program in patients with non-small cell lung cancer (NSCLC) which includes the Phase III studies, STARTa and INSPIREb. The treatment and enrollment in these studies will restart after approval by the local regulatory authorities and ethics committees.

17 Jun 2010

Abbott, Neurocrine enter collaboration to develop, commercialize elagolix for endometriosis-related pain

Abbott and Neurocrine Biosciences, Inc. today announced that they have entered into a collaboration agreement to develop and commercialize elagolix for the treatment of endometriosis-related pain. Elagolix is a novel, first-in-class oral gonadotropin-releasing hormone (GnRH) antagonist, which has recently completed a phase IIb study in endometriosis. In addition to endometriosis, elagolix will be evaluated for the treatment of uterine fibroids.

16 Jun 2010

IRIN, IPS examine pending U.S. legislation to address global hunger, FGM

IRIN reports on the Global Food Security Act, a bill aimed at expanding the U.S. government's role in combatting hunger around the world. The legislation is co-sponsored by Sens. Richard Lugar (R-Ind.) and Bob Casey (D-Pa.).

15 Jun 2010

New path involving "innocent spectators" to defeat systemic sclerosis

There is a new path to defeat systemic sclerosis, also called scleroderma because of the hardening of the skin of the patients (from Greek skleros, "hard", and derma, "skin"). This path involves the B-cell of the immune system, so far only considered "innocent spectators," as Catholic University rheumatologist Gianfranco Ferraccioli, among the authors of the important research, puts it.

14 Jun 2010

FDA clears U.Va.'s SpermCheck Fertility at-home test

Couples will soon have a new tool in diagnosing male infertility - without the expense and inconvenience associated with a trip to a specialist's office.

14 Jun 2010

Vitrolife enters into two year collaboration agreement with University of Melbourne

Vitrolife has entered into a two year collaboration agreement with University of Melbourne regarding collaboration with the stem cells expertise of the development of clinical grade stem cell media.

14 Jun 2010

Children born after ART at increased risk of congenital malformation

Couples considering undergoing assisted reproductive technology (ART) treatment should be informed about the increased risk of congenital malformation posed by the use of ART, the annual conference of the European Society of Human Genetics will hear today (Monday). Dr. G-raldine Viot, a clinical geneticist at the Maternit- Port Royal hospital, Paris, France, will say that she believed that most doctors working in ART clinics in France only told couples about such risks if they were asked specific questions.

14 Jun 2010

In vitro fertilization ups the risk of birth defects: study

Researchers have found from a large scale study that in vitro fertilization of IVF is associated with an increased risk of birth defects in the baby. They urge doctors treating patients with infertility to routinely warn them about these risks. The study involved 33 centers for IVF in France and covered over 15,000 births from 2003 to 2007. This study is the largest till date.

14 Jun 2010

Merck Serono reports long-term follow-up data of cilengitide Phase II study for recurrent glioblastoma

Merck Serono, a division of Merck KGaA, Darmstadt, Germany announced today that long-term follow-up data of a randomized Phase II study of two cilengitide doses in recurrent glioblastoma were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

7 Jun 2010

Diagnosis of antiovarian autoantibodies in infertile women help in approaches for assisted reproduction

Studies on the ovarian antigens and its corresponding specific antibodies have showed the relationship between the incidences of antiovarian autoantibodies and the clinical mani-festation of ovarian dysfunction and infertility in women.

4 Jun 2010

PregLem reports positive Phase III data from PEARL I study of Esmya for uterine fibroids

PregLem, the European specialty biopharmaceutical company focused on women's reproductive medicine, announces positive Phase III data from its second pivotal study (PEARL I) for its lead product Esmya (ulipristal acetate), as an effective treatment for uterine fibroids (myoma) - a condition that affects millions of women worldwide.

4 Jun 2010